PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications

Launched by UNIVERSITY OF LEEDS · Jun 4, 2024

Keywords

ClinConnect Summary

The PROSpECT-PRIOR-2-CHEMO trial is a study designed to see if treating dental health issues before starting chemotherapy can help patients with certain blood cancers, like myeloma, avoid complications. The goal is to improve their overall health and ensure that their chemotherapy can proceed smoothly without delays. This is important because good oral health may help reduce problems like mouth sores and infections that can arise during treatment.

To be part of this trial, participants need to be adults who are scheduled to receive chemotherapy and have moderate to high oral health risks, such as having multiple cavities or signs of infection in their mouth. Participants will receive care for their dental issues before starting chemotherapy. It's important to note that people with a history of certain treatments or those who cannot attend required appointments may not be eligible. The trial is not yet recruiting, but it aims to improve the health journey for patients facing chemotherapy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria (mod-high/risk trial participants):
• * Adults (≥ 18years) with scheduled Chemotherapy. Specifically, patients who meet the following diagnosis and treatment window requirements:
• • Myeloma- Autologous Stem Cell Transplantation (ASCT) before high-dose myeloablative CT.
• • Haematological cancers suitable for Allografts Stem Cell Transplant (SCT) before CT
• * Moderate / High Oral Health Risk Assessment - any one of the following:
• • Clinical evidence of caries (2+ teeth)
• • Clinical evidence on soft and hard tissue examination of infection, sinus, swelling or tenderness
• • BPE code 3-4 in any remaining sextant
• • BPE code 1-2 with \>30% BOP
• • The patient is fully informed, has received PIS (patient information sheet) and considered during a 'cooling-off' period, is competent to consent, and is able to comply with minimum attendance requirements
• Exclusion Criteria:
• • Have a history of head and neck radiotherapy
• • Have been treated with Denusomab, Bevacizumab, Sunitinib or Aflibercept within 9 months of the MDT date.
• • Insufficient teeth \[defined as \<2\]
• • Are incapable of providing informed written consent
• • Are unable to comply with minimum attendance requirements